Curasight presents at HC Andersen Capital

December 13, 2021

Regulatory

Curasight A/S (“Curasight” or the “Company”) CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present a Deep Dive event in Prostate Cancer at HC Andersen Capital, 15 December 2021.

The presentation will be webcasted live 11:00 - 12:00 (CET), Wednesday 15 December 2021.

For more information – please click here

The presentation will be in English.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Downloads

Press Release 13-12-2021

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.